You can buy or sell ACHV and other stocks, options, ETFs, and crypto commission-free!
Achieve Life Sciences, Inc. Common Shares, also called Achieve Life Sciences, is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Read More Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Vancouver, British Columbia
52 Week High
52 Week Low
Yahoo FinanceMay 7
Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
SEATTLE and VANCOUVER, British Columbia , May 7, 2019 /CNW/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will report its first quarter 2019 financial results on Wednesday, May 15, 2019 . Company management will host a conference call and live webcast at 4:30pm Eastern Time to provide an overview of financial results, the clinical development program, and...
Markets InsiderApr 24
Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, April 24, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the last study visit for the last subject enrolled in the ORCA-1 trial occurred on April 23, 2019. ORCA-1 topline efficacy and safety data are expected to be announced by the end of the second quarter. ORCA-1 is the first in Achieve's O...
-$0.63 per share
-$0.88 per share